Small Mobile stem (SMS) cell therapy / SMSbiotech - LARVOL DELTA

SMSbiotech Initiates Groundbreaking Phase 1 Human Clinical Trial for COPD (Businesswire) - "The Phase 1 study, titled 'A study to investigate small mobile stem cells (SMS cells) in participants aged 39 to 69 years with chronic obstructive pulmonary disease,' will enroll 18 COPD patients."

New P1 trial • Chronic Obstructive Pulmonary Disease

SMSbiotech Receives Green Light for Phase I Clinical Trial in Australia, Targeting COPD (Businesswire) - "SMSbiotech has announced a significant milestone in its pursuit of its regenerative medicine technology, securing approval to commence a Phase I clinical trial in Australia (registration number: ANZCTR12624001140549p). The trial will focus on evaluating the safety and tolerability of the company's innovative Small Mobile stem (SMS) cell therapy for Chronic Obstructive Pulmonary Disease (COPD)....The Phase I trial will primarily assess the safety and tolerability of the therapy in human subjects. The study will enroll 18 patients with mild to moderate COPD in accordance with the patient enrollment criteria outlined by the US FDA."

New P1 trial • Chronic Obstructive Pulmonary Disease